Covetrus (Covetrus) Cash And Cash Equivalents : $87 Mil (As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Covetrus Cash And Cash Equivalents?

Covetrus's quarterly cash and cash equivalents declined from Dec. 2021 ($183.00 Mil) to Mar. 2022 ($117.00 Mil) but then stayed the same from Mar. 2022 ($117.00 Mil) to Jun. 2022 ($87.00 Mil).

Covetrus's annual cash and cash equivalents increased from Dec. 2019 ($130.00 Mil) to Dec. 2020 ($290.00 Mil) but then declined from Dec. 2020 ($290.00 Mil) to Dec. 2021 ($183.00 Mil).

Covetrus Cash And Cash Equivalents Historical Data

The historical data trend for Covetrus's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covetrus Cash And Cash Equivalents Chart

Covetrus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash And Cash Equivalents

Get a 7-Day Free Trial

16.66

23.00

130.00

290.00

183.00

Covetrus Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Cash And Cash Equivalents	Get a 7-Day Free Trial															230.00	187.00	183.00	117.00	87.00

Covetrus Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Covetrus (NAS:CVET) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Covetrus Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Covetrus's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Covetrus (Covetrus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Covetrus Inc (NAS:CVET) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Custom House Street, Portland, ME, USA, 04101

Website

https://www.covetrus.com

Covetrus Inc is an animal-health technology and services company dedicated to supporting the companion, equine, and large-animal veterinary markets. Its segments are North America, Europe and the Asia Pacific (APAC) and Emerging Markets. The company's services include supply chain services, software solutions, and prescription management.

Executives

Benjamin Wolin	director	C/O EVERYDAY HEALTH, INC., 345 HUDSON STREET, 16TH FLOOR, NEW YORK NY 10014
Edward Mcnamara	director	C/O COVETRUS, INC., 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Rebecca Ann Kidd	officer: Head of Global Operations	7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Matthew Malenfant	officer: Chief Commercial Officer	7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Andrew B. Coxhead	officer: See Remarks	C/O RR DONNELLEY, 111 SOUTH WACKER DRIVE, CHICAGO IL 60606
Dustin Finer	officer: Chief People Officer	7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Laura J Phillips	officer: See Remarks	7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Michael Ellis	officer: See Remarks	C/O HS SPINCO, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Timothy Ludlow	officer: See Remarks	C/O COVETRUS, INC., 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Georgina Wraight	officer: See Remarks	C/O COVETRUS, INC., 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
David Stuart Hinton	officer: See Remarks	C/O HS SPINCO, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Providenti Anthony C. Jr.	officer: See Remarks	3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jamey S Seely	officer: General Counsel and Secretary	C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Sandra E Peterson	director	100 PARSONS POND DRIVE, FRANKLIN LAKES NJ 07417